This is especially dangerous because MedGemma might recognize the subtype from the image and describe subtype-specific features in the report — meaning the report essentially contains the label in natural language form. If so, your SGAM isn't learning to attend to morphological features; it's learning to read the answer from the text. You need to control for this.

Additional Weaknesses (Reviewer #2's Ammunition)
No attention visualizations. You claim SGAM directs attention to "diagnostically relevant regions" but show zero attention maps. This is the easiest win you're leaving on the table.

No computational cost analysis. How much overhead does SGAM + fusion + dual encoder add vs. vanilla ProtoNet? Inference time? Memory? A clinician cares about this.

The consistency loss is suspicious. $\mathcal{L}{\text{consist}} = |f{\text{final}} - v'|^2$ penalizes the fused representation for being different from the visual-only feature. This actively fights against semantic guidance — you're telling the model "don't change too much from visual-only." Why would this help? This needs ablation and justification.

Temperature $\tau$ is hardcoded. You use $\tau = 0.07$ for InfoNCE (from CLIP) without any justification that this transfers to histopathology prototypical learning. Learnable temperature is standard now.

No statistical significance tests. Paired t-tests or Wilcoxon signed-rank between methods are mandatory for Q1.

Related work misses key papers. AM3 (Xing et al., 2019) — literally does "adaptive modulation with semantic prototypes for few-shot learning." TRAML (Li et al., 2020) — task-relevant auxiliary for multi-label FSL. These are direct competitors you don't cite or compare against.

Critical Fixes (Minimum for Q1 Consideration)
Add the Bayesian prototype formulation. Replace vanilla mean prototypes with a proper Bayesian update where the semantic anchor serves as prior. This is your actual novelty — implement it and prove it mathematically.

Add 2+ datasets. At minimum: one more medical (NCT-CRC-HE or PatchCamelyon) and one natural (CUB-200 or miniImageNet). Cross-domain experiments are expected.

Add 5+ external baselines. ProtoNet, MatchingNet, FEAT, DeepEMD, and at least one recent 2023-2024 method. Use their published numbers or rerun with BiomedCLIP backbone for fair comparison.

Add attention visualizations. Show SGAM attention maps overlaid on histopathology images, ideally with pathologist commentary. This is your strongest qualitative argument.

Add report quality analysis. Sample 50-100 reports, have a domain expert score them, or compute BERTScore/BLEU against textbook descriptions. Address the label leakage concern explicitly.

Increase to 10,000 evaluation episodes with proper CI and significance tests.

Add t-SNE/UMAP of embeddings showing visual-only vs. SGAM-fused features — demonstrate that semantic guidance actually improves class separation.

Journal Recommendations
Rank	Venue	Why
1	Medical Image Analysis (Q1)	Best fit if you add datasets + Bayesian formulation + attention maps. They value clinical relevance.
2	IEEE TMI (Q1)	Needs stronger baselines and significance tests. They're rigorous on experimental protocol.
3	MICCAI 2025 Workshop / MIDL (Conference)	Current paper is closer to workshop-level. Lower bar, faster turnaround, good for establishing the idea before a journal extension.
Honest recommendation: Submit to MIDL or a MICCAI workshop first with what you have now, get reviewer feedback, then expand to a journal submission with Bayesian formulation + multi-dataset + proper baselines.

Bottom Line
The writing is solid and the system design is competent engineering. But "I combined BiomedCLIP + cross-attention + ProtoNet" is not a Q1 contribution. The Bayesian anchor idea you mentioned in your pitch — that could be the contribution, but it's not in the paper yet. Add it, prove it mathematically, and back it with serious experiments. Then you have a shot.